Lancet Infectious Diseases

Article	Citations
Untold Lassa fever story: a physician's lived experience	859179314
An interactive web-based dashboard to track COVID-19 in real time	7589
Estimates of the severity of coronavirus disease 2019: a model-based analysis	2632
Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study	2487
Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study	2418
Early dynamics of transmission and control of COVID-19: a mathematical modelling study	1686
Viral load of SARS-CoV-2 in clinical samples	1311
Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study	1245
Viral dynamics in mild and severe cases of COVID-19	1216
A minimal common outcome measure set for COVID-19 clinical research	1092
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial	1023
A clinical case definition of post-COVID-19 condition by a Delphi consensus	914
Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study	914
Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics	904
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial	868
Clinical and virological data of the first cases of COVID-19 in Europe: a case series	862
Real estimates of mortality following COVID-19 infection	841
COVID-19: combining antiviral and anti-inflammatory treatments	828
Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study	808
Global impact of the first year of COVID-19 vaccination: a mathematical modelling study	757
Convalescent plasma as a potential therapy for COVID-19	725
Clinical features and management of human monkeypox: a retrospective observational study in the UK	703
Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study	692
Scientific and ethical basis for social-distancing interventions against COVID-19	638
Can we contain the COVID-19 outbreak with the same measures as for SARS?	628

Effectiveness of isolation, testing, contact tracing, and physical distancing on reducing transmission of SARS-CoV-2 in different settings: a mathematical modelling study	625
Association between mobility patterns and COVID-19 transmission in the USA: a mathematical modelling study	607
The value of antimicrobial peptides in the age of resistance	565
Interventions to mitigate early spread of SARS-CoV-2 in Singapore: a modelling study	557
COVID-19 and multisystem inflammatory syndrome in children and adolescents	545
Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study	538
Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study	533
Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance	529
Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study	525
Genomic evidence for reinfection with SARS-CoV-2: a case study	514
Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study	509
Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study	465
Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study	451
What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2	449
Asymptomatic cases in a family cluster with SARS-CoV-2 infection	442
Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study	417
A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and politicisation	406
COVID-19 and medical education	402
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical	387
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, mult	383
Stigma during the COVID-19 pandemic	362
Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case series	345
Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study	343
The many estimates of the COVID-19 case fatality rate	338
The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-CoV-2: a modelling study across 131 countries	337
Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study	333
Rapid implementation of SARS-CoV-2 sequencing to investigate cases of health-care associated COVID-19: a prospective genomic surveillance study	326
Risk of COVID-19 in health-care workers in Denmark: an observational cohort study	325
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2	317
Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison	301
Exaggerated risk of transmission of COVID-19 by fomites	296
Demographic and clinical characteristics of confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: an observational analysis	291
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial	289
The COVID-19 infodemic	284
Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study	280
COVID-19 pneumonia: what has CT taught us?	259
Pooling of samples for testing for SARS-CoV-2 in asymptomatic people	247
Serology testing in the COVID-19 pandemic response	242
Smell and taste dysfunction in patients with COVID-19	239
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial	232
SARS-CoV-2 infection and transmission in educational settings: a prospective, cross-sectional analysis of infection clusters and outbreaks in England	231
Long-term consequences of COVID-19: research needs	229
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised	227
Scaling up COVID-19 rapid antigen tests: promises and challenges	225
Taking the right measures to control COVID-19	224
Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT	223
Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression	222
Assessment of WHO antibiotic consumption and access targets in 76 countries, 2000–15: an analysis of pharmaceutical sales data	222
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial	218
Covert COVID-19 and false-positive dengue serology in Singapore	217

Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study	215
Willingness to vaccinate against COVID-19 in Australia	211
Changes in colistin resistance and mcr-1 abundance in Escherichia coli of animal and human origins following the ban of colistin-positive additives in China: an epidemiological comparative study	211
SARS-CoV-2: virus dynamics and host response	209
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial	208
Connecting clusters of COVID-19: an epidemiological and serological investigation	204
Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study	201
COVID-19 in Latin America	200
Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-cont	200
COVID-19 in health-care workers in three hospitals in the south of the Netherlands: a cross-sectional study	199
Open access epidemiological data from the COVID-19 outbreak	191
Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical tri	191
Intention to vaccinate against COVID-19 in Australia	187
Monitoring approaches for health-care workers during the COVID-19 pandemic	186
COVID-19 in children: the link in the transmission chain	185
Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study	181
The indirect impact of COVID-19 on women	181
COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study	179
Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective analysis	178
Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden	177
Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design	176
Household transmission of SARS-CoV-2 and risk factors for susceptibility and infectivity in Wuhan: a retrospective observational study	176
The important role of serology for COVID-19 control	175
Likelihood of survival of coronavirus disease 2019	174
Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-PCR testing: a systematic review and meta-analysis	172
What reinfections mean for COVID-19	166
The global incidence and diagnosis of fungal keratitis	165
COVID-19 with spontaneous pneumomediastinum	164
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial	163
Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial	163
Baricitinib for COVID-19: a suitable treatment?	161
Global shortage of personal protective equipment	161
Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study	161
SARS-CoV-2 seroprevalence and transmission risk factors among high-risk close contacts: a retrospective cohort study	160
The first 2019 novel coronavirus case in Nepal	159
The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis	157
SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity	157
The Lancet Infectious Diseases Commission on antimicrobial resistance: 6 years later	155
Utility of hyposmia and hypogeusia for the diagnosis of COVID-19	155
SeroTracker: a global SARS-CoV-2 seroprevalence dashboard	154
Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and	153
Comparison of molecular testing strategies for COVID-19 control: a mathematical modelling study	150
Monkeypox virus isolation from a semen sample collected in the early phase of infection in a patient with prolonged seminal viral shedding	149
Generation time of the alpha and delta SARS-CoV-2 variants: an epidemiological analysis	147
Individual quarantine versus active monitoring of contacts for the mitigation of COVID-19: a modelling study	147
Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: a systematic review and meta-analysis	145
Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wav	145
ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5	144
Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study	144
Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis	144
Guidelines for pregnant women with suspected SARS-CoV-2 infection	139
Indirect effects of the COVID-19 pandemic on malaria intervention coverage, morbidity, and mortality in Africa: a geospatial modelling analysis	136
Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial	135
Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies	132
China's successful control of COVID-19	129
Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study	127
Monkeypox outbreaks outside endemic regions: scientific and social priorities	126
COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England	125
SARS-CoV-2 and the human-animal interface: outbreaks on mink farms	124
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape	124
Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US	123
Pandemic potential of 2019-nCoV	122
COVID-19 disrupts vaccine delivery	122
Concerns and motivations about COVID-19 vaccination	121
Bell's palsy and SARS-CoV-2 vaccines	121
Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study	121
Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial	120
Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial	120
Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review	120
Rural areas at risk during COVID-19 pandemic	119
Prioritising COVID-19 vaccination in changing social and epidemiological landscapes: a mathematical modelling study	118
Hospitalisation among vaccine breakthrough COVID-19 infections	116
Low risk of SARS-CoV-2 transmission by fomites in real-life conditions	116
Estimating case fatality rates of COVID-19	116
Towards an accurate and systematic characterisation of persistently asymptomatic infection with SARS-CoV-2	113
Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study	113
Estimation of COVID-19 outbreak size in Italy	113
Protective immunity after recovery from SARS-CoV-2 infection	112
Prevention of monkeypox with vaccines: a rapid review	110
SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study	110

Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled	109
Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study	108
The status of tuberculosis vaccine development	108
Monoclonal antibody therapies against SARS-CoV-2	107
Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2	106
Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study	105
Vaccinology: time to change the paradigm?	105
Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB	103
RT-PCR for SARS-CoV-2: quantitative versus qualitative	103
Omicron sublineage BQ.1.1 resistance to monoclonal antibodies	99
Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe	99
Tracking the 2022 monkeypox outbreak with epidemiological data in real-time	99
Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial	98
The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation	97
A family cluster of SARS-CoV-2 infection involving 11 patients in Nanjing, China	97
Epidemiology of respiratory syncytial virus in children younger than 5 years in England during the COVID-19 pandemic, measured by laboratory, clinical, and syndromic surveillance: a retrospective obse	96
The urgent need for metallo-β-lactamase inhibitors: an unattended global threat	94
Serology-informed estimates of SARS-CoV-2 infection fatality risk in Geneva, Switzerland	94
Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis	94
Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study	94
Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant	94
SARS-CoV-2 shedding and seroconversion among passengers quarantined after disembarking a cruise ship: a case series	93
Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and An	93
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial	93
New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial	93
Disease X: accelerating the development of medical countermeasures for the next pandemic	92
Understanding COVID-19: what does viral RNA load really mean?	92
Association of tiered restrictions and a second lockdown with COVID-19 deaths and hospital admissions in England: a modelling study	91
BCG-induced non-specific effects on heterologous infectious disease in Ugandan neonates: an investigator-blind randomised controlled trial	90
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (CO	90
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study	90
Molecular epidemiology of resistance to antimalarial drugs in the Greater Mekong subregion: an observational study	89
Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial	88
The world's largest COVID-19 vaccination campaign	88
The place for remdesivir in COVID-19 treatment	87
Appropriateness of antibiotic prescriptions in ambulatory care in China: a nationwide descriptive database study	86
Zoonotic spillover infections with Borna disease virus 1 leading to fatal human encephalitis, 1999–2019: an epidemiological investigation	85
Xpert MTB/RIF Ultra versus Xpert MTB/RIF for the diagnosis of tuberculous meningitis: a prospective, randomised, diagnostic accuracy study	85
Outbreak of coronavirus disease 2019	84
Genomic-informed pathogen surveillance in Africa: opportunities and challenges	84
Exhaled Mycobacterium tuberculosis output and detection of subclinical disease by face-mask sampling: prospective observational studies	83
PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study	83
Long COVID in the skin: a registry analysis of COVID-19 dermatological duration	83
Lung fibrosis: an undervalued finding in COVID-19 pathological series	82
Sources of persistent malaria transmission in a setting with effective malaria control in eastern Uganda: a longitudinal, observational cohort study	82
COVID-19 human challenge studies: ethical issues	82
Defining the determinants of vaccine uptake and undervaccination in migrant populations in Europe to improve routine and COVID-19 vaccine uptake: a systematic review	81
Epidemic preparedness in urban settings: new challenges and opportunities	81
Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase	80
100 years of Mycobacterium bovis bacille Calmette-Guérin	80
Global burden and trends of sexually transmitted infections from 1990 to 2019: an observational trend study	79
Risk predictors of progression to severe disease during the febrile phase of dengue: a systematic review and meta-analysis	79
Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5	78
SARS-CoV-2 RNA more readily detected in induced sputum than in throat swabs of convalescent COVID-19 patients	78
Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial	78
Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study	77
First detection of SARS-CoV-2 spike protein N501 mutation in Italy in August, 2020	77
Hydroxychloroquine prophylaxis for COVID-19 contacts in India	77
Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM	76
Efficacy, immunogenicity, and safety of an oral influenza vaccine: a placebo-controlled and active-controlled phase 2 human challenge study	76
ChatGPT and antimicrobial advice: the end of the consulting infection doctor?	76
Xpert MTB/RIF Ultra for the diagnosis of HIV-associated tuberculous meningitis: a prospective validation study	75
Hand hygiene in health care: 20 years of ongoing advances and perspectives	75
Management of pregnant women infected with COVID-19	75
The intersection of COVID-19 and mental health	75
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial	74
Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study	74
The scientific and ethical feasibility of immunity passports	74
Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3	74
Performance and operational feasibility of antigen and antibody rapid diagnostic tests for COVID-19 in symptomatic and asymptomatic patients in Cameroon: a clinical, prospective, diagnostic accuracy s	74
Chloroquine or hydroxychloroquine for prophylaxis of COVID-19	74
Re-examining causes of surgical site infections following elective surgery in the era of asepsis	71
The importance of understanding the infectious microenvironment	71
Mortality and critical care unit admission associated with the SARS-CoV-2 lineage B.1.1.7 in England: an observational cohort study	71
Same-day SARS-CoV-2 antigen test screening in an indoor mass-gathering live music event: a randomised controlled trial	71
Circulation of non-polio enteroviruses in 24 EU and EEA countries between 2015 and 2017: a retrospective surveillance study	70
Viral loads in clinical samples of men with monkeypox virus infection: a French case series	69
Invasive pneumococcal disease incidence in children and adults in France during the pneumococcal conjugate vaccine era: an interrupted time-series analysis of data from a 17-year national prospective	68
Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study	68
Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation	68
Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant	67
Complications and mortality of non-typhoidal salmonella invasive disease: a global systematic review and meta-analysis	67
Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controll	67
Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant	67
The state of vaccine safety science: systematic reviews of the evidence	67
Accuracy of HBeAg to identify pregnant women at risk of transmitting hepatitis B virus to their neonates: a systematic review and meta-analysis	66
Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac	66
Cavitary tuberculosis: the gateway of disease transmission	65
Measuring the effects of COVID-19-related disruption on dengue transmission in southeast Asia and Latin America: a statistical modelling study	65
Gaps in India's preparedness for COVID-19 control	64
Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccinati	64
Hospital-treated infectious diseases and the risk of dementia: a large, multicohort, observational study with a replication cohort	64
Interferon-γ release assays or tuberculin skin test for detection and management of latent tuberculosis infection: a systematic review and meta-analysis	64
Case isolation, contact tracing, and physical distancing are pillars of COVID-19 pandemic control, not optional choices	64
Epidemiological and clinical characteristics of patients with monkeypox in the GeoSentinel Network: a cross-sectional study	62